Equities Analysts Issue Forecasts for CMPX FY2028 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Equities research analysts at HC Wainwright boosted their FY2028 EPS estimates for Compass Therapeutics in a research note issued on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.94 for the year, up from their prior estimate of $0.85. HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share.

Other analysts have also issued reports about the stock. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Wednesday, August 7th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Monday, September 16th.

Compass Therapeutics Price Performance

NASDAQ:CMPX traded down $0.04 during trading hours on Thursday, hitting $1.66. The stock had a trading volume of 32,726 shares, compared to its average volume of 431,274. The company has a 50 day simple moving average of $1.75 and a two-hundred day simple moving average of $1.42. The firm has a market capitalization of $227.71 million, a price-to-earnings ratio of -4.57 and a beta of 0.92. Compass Therapeutics has a one year low of $0.77 and a one year high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CMPX. Rovin Capital UT ADV bought a new position in Compass Therapeutics in the 3rd quarter valued at $25,000. Intech Investment Management LLC purchased a new position in shares of Compass Therapeutics in the third quarter worth $30,000. SG Americas Securities LLC boosted its position in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after buying an additional 5,515 shares during the last quarter. Bleakley Financial Group LLC acquired a new position in shares of Compass Therapeutics in the 1st quarter valued at about $80,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Compass Therapeutics during the second quarter valued at $41,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.